Donald Trump urges car giants Ford, General Motors and Fiat Chrysler to build new plants in the US

US President Donald Trump has urged the heads of car companies to boost production in the US and promised to slash “out of control” regulations to attract more investment.Trump yesterday also signed executive orders for construction of the controversial Keystone XL and Dakota Access oil pipelines, which had been thrown into doubt under his predecessor Barack Obama over environmental concerns. Wednesday 25 January 2017 12:04 am Donald Trump urges car giants Ford, General Motors and Fiat Chrysler to build new plants in the US whatsapp Vowing to revive the US manufacturing industry, Trump backed the pipelines as long as American steel was used.Read more: Trump bump: US manufacturing activity expands at fastest rate since 2014Paving the way to fast track other infrastructure projects, he signed another executive order to slash environmental reviews that he described as an “incredibly cumbersome, long, horrible permitting process.”In his meeting with the chief executives of General Motors, Ford and Fiat Chrysler, Trump suggested he would overhaul regulations as part of a bid to entice the car makers to build new plants.Read more: Hyundai and General Motors up US investment in the wake of Trump tax threat whatsapp by Taboolaby TaboolaSponsored LinksSponsored LinksPromoted LinksPromoted LinksYou May LikeMisterStoryWoman Files For Divorce After Seeing This Photo – Can You See Why?MisterStoryAtlantic MirrorA Kilimanjaro Discovery Has Proved This About The BibleAtlantic MirrorUnify Health LabsRandy Jackson: This 3 Minute Routine Transformed My HealthUnify Health LabsSwift VerdictChrissy Metz, 39, Shows Off Massive Weight Loss In Fierce New PhotoSwift VerdictHealthyGemBaby Has Never Eaten Sugar Or Carbs, Wait Till You See Her TodayHealthyGemFinanceChatterViewers Had To Look Away When This Happened On Live TVFinanceChatterinvesting.comThe Military Spent $1 Billion On this New Vehicle, And Here’s The First Lookinvesting.comMaternity WeekAfter Céline Dion’s Major Weight Loss, She Confirms What We Suspected All AlongMaternity WeekLiver Health1 Bite of This Melts Belly And Arm Fat (Take Before Bed)Liver Health Share Steven Scott More From Our Partners Native American Tribe Gets Back Sacred Island Taken 160 Years Agogoodnewsnetwork.orgFlorida woman allegedly crashes children’s birthday party, rapes teennypost.comAstounding Fossil Discovery in California After Man Looks Closelygoodnewsnetwork.org980-foot skyscraper sways in China, prompting panic and evacuationsnypost.comPolice Capture Elusive Tiger Poacher After 20 Years of Pursuing the Huntergoodnewsnetwork.orgBiden received funds from top Russia lobbyist before Nord Stream 2 giveawaynypost.comBrave 7-Year-old Boy Swims an Hour to Rescue His Dad and Little Sistergoodnewsnetwork.orgA ProPublica investigation has caused outrage in the U.S. this weekvaluewalk.comRussell Wilson, AOC among many voicing support for Naomi “We want regulations, but we want regulations that mean something,” Trump said.Trump has previously attacked carmakers for moving plants offshore and threatened to impose a 35 per cent tariff on imported vehicles.The three bosses – GM’s Mary Barra, Ford’s Mark Fields and Fiat Chrysler’s Sergio Marchionne – later praised Trump’s decision to abandon the 12 nation Trans Pacific Partnership (TPP) trade deal, which they said was not tough enough on currency manipulation by Asian countries.Read more: Xi and Trump have fired the opening salvoes of the coming trade war“We’re very encouraged by the President and the economic policies that he’s forwarding,” Fields said.Trump’s focus on business policies came as the Nasdaq Composite ticked to a record high yesterday, closing at 5,600.96 points. read more

In the afterlife, Unalaska’s eagles find purpose at national repository

first_imgAlaska Native Arts & Culture | Aleutians | Arts & Culture | Nation & World | WildlifeIn the afterlife, Unalaska’s eagles find purpose at national repositoryAugust 30, 2017 by Berett Wilber, KUCB-Unalaska Share:When bald eagles die in Unalaska, it’s the beginning of a long journey. Literally.Many of them travel thousands of miles and find second lives in the Lower 48.Audio Player Up/Down Arrow keys to increase or decrease volume.Damian Lopez-Plancarte is “the eagle guy” in Unalaska. He responds to calls for eagle assistance, and collects and ships dead eagles on to the National Repository. (Photo by Berett Wilber/KUCB)When Damian Lopez-Plancarte walks into the Wildlife Trooper office and opens the freezer, it looks like Thanksgiving.The shelves are jammed full of turkey-shaped items wrapped in plastic.But none of them are turkeys.“Here we have one, two, three four, five dead eagles,” said Lopez Plancarte, counting each one.When a raptor is found dead, he gets the call to remove the bird. He bags the carcass and stores it here, along with other freezer goods.“That’s an ice cream sandwich,” he points out. “Keep ‘em in the same freezer.”These eagles may have an unusual icy grave, but soon they’ll begin a journey that could take them more than 3000 miles across America. Why?The Bald and Golden Eagle Protection Act of 1940 made it a federal crime for anyone to possess eagle parts — and the punishment is severe.Get caught with even one feather, and you could receive a $200,000 fine, a yearlong prison sentence, or both.The exception is for members of federally recognized tribes, many of whom use eagle feathers, talons and other parts in ceremonies or as spiritual objects.But if taking, transporting and buying eagle parts is still illegal, then how are indigenous people supposed to get them?The answer is the National Eagle Repository in Colorado.Dead eagles from across the nation are shipped there, including those from Unalaska.Sarah Metzer works at the repository. Her job includes delivering educational programs and sorting through two giant walk-in freezers full of eagle carcasses.“Wanting to ensure that we protect the constitutionally protected right of religious freedom, our facility turns those eagles around,” Metzer said. “We’re able to distribute the parts and feathers to members of federally recognized Native American tribes.”Last year, she says the repository received 2,700 eagles and filled nearly 4,000 orders, or more than seven eagles a day, and the rate keeps climbing.“We’re looking at getting a third freezer,” Metzer said.Most orders are from the Southwest, where the feathers are used for powwows and graduations, as well as gifts and headdresses.“It’s a pretty special thing, knowing there’s a recipient on the other end,” Metzer said. “This eagle will live on, and its spirit will live on through that applicant.”But the wait can be long and frustrating for those who feel the federal government shouldn’t be in charge of distributing ceremonial objects or regulating indigenous spirituality.If you placed an order today, it would take six months to get a whole bald eagle. Half that for 20 loose feathers. A golden eagle takes more than two years.That makes it tempting to pick feathers up off the beach. But now, indigenous people can do just that.After decades of an informal policy to look the other way when Native Americans had non-repository feathers, the Justice Department issued a memo in 2012., which allows indigenous people to pick up and possess “culturally significant” eagle parts — even if they don’t come from the repository — as long as they don’t sell the parts or kill the eagles.While the repository does fill orders from Alaska, chances are slim that Unalaska’s eagles will find themselves back on the island in the afterlife.Share this story:last_img read more

Ukip attacks BBC over EU funds after stinging mockumentary

first_img More From Our Partners Astounding Fossil Discovery in California After Man Looks Closelygoodnewsnetwork.orgA ProPublica investigation has caused outrage in the U.S. this weekvaluewalk.comNative American Tribe Gets Back Sacred Island Taken 160 Years Agogoodnewsnetwork.orgInside Ashton Kutcher and Mila Kunis’ not-so-average farmhouse estatenypost.comBrave 7-Year-old Boy Swims an Hour to Rescue His Dad and Little‘Neighbor from hell’ faces new charges after scaring off home buyersnypost.comRussell Wilson, AOC among many voicing support for Naomi Osakacbsnews.comFlorida woman allegedly crashes children’s birthday party, rapes teennypost.comPolice Capture Elusive Tiger Poacher After 20 Years of Pursuing the Ukip attacks BBC over EU funds after stinging mockumentary UKIP yesterday launched a stinging attack on the BBC ahead of what the party labelled a “pro-EU” mockumentary that was aired on BBC 4 last night.The Storyville programme “The Great European Disaster Movie”, authored by Italian director Annalisa Piras and ex-editor of The Economist Bill Emmott, envisions a dystopian post-EU future where rioting and the far right dominate the continent and Isis is on the borders of central Europe.In this fictional future Nigel Farage is the Prime Minister of “Great England” and is presiding over the deportation of all immigrants who arrived in the UK over the past decade.Ukip pointed out the Beeb had received £22m from the EU in the last seven years while Ukip MP Mark Reckless claimed Emmott told him the Corporation had received EU money to help make tonight’s film. The BBC replied that no EU money was used in the making of the “fictional” programme. Sunday 1 March 2015 10:49 pm Share whatsapp Express KCS center_img by Taboolaby TaboolaSponsored LinksSponsored LinksPromoted LinksPromoted LinksYou May LikeMoneyPailShe Was A Star, Now She Works In ScottsdaleMoneyPailMaternity WeekA Letter From The Devil Written By A Possessed Nun In 1676 Has Been TranslatedMaternity Weekzenherald.com20 Rules Genghis Khan’s Army Had To Live Byzenherald.comMagellan TimesThis Is Why The Roy Rogers Museum Has Been Closed For GoodMagellan TimesWorldemandCanal Drained For First Time And They Find ThisWorldemandComedyAbandoned Submarines Floating Around the WorldComedyGameday NewsNBA Wife Turns Heads Wherever She GoesGameday NewsTheFashionBallPrince Harry Admits Meghan Markle May Not Be The OneTheFashionBallNoteableyKirstie Alley Is So Skinny Now And Looks Like A BarbieNoteabley Show Comments ▼ Tags: BBC whatsapp last_img read more

News / All-cargo Midex Airlines folds its wings, while court backs Martinair restructure

first_imgSome observers also suggested that there was little airline expertise in its management, despite at one time having $500m in investment to play with.It switched, fairly quickly, from a majority of scheduled services to mostly ad hoc charters, and opened up routes to the military hotspots of Afghanistan, Iraq and Libya, which were in the process of rebuilding, while bringing 747-200Fs into the fleet to allow it to carry large-volume cargo. It had hoped to carry passengers too, but this dream came to nothing.In recent years – in fact, in some cases stretching almost back to its launch – it has struggled with a poor reputation. Its licence was threatened with suspension in 2010, while pilots have consistently complained of poor safety practices and of not being paid.In March, its three remaining 747-200Fs appeared to be parked at its latest hub, in Sharjah. And in June, reported CH Aviation, it shut its doors – “fortunately for aviation” reported one former pilot. It is not clear what the plans are for the aircraft.Meanwhile, at another troubled all-cargo carrier, Martinair, a Dutch court has found that, despite a “procedural” mistake in the way it has planned its restructuring, the carrier will be permitted to continue its plans for fleet cuts. Martinair’s works council had submitted several complaints to the Enterprise Chamber, which largely brushed them aside, reports the Dutch press.The judge found that the works council should have been better informed about the cuts, but that the restructuring was necessary and can be done quickly, owing to the company’s “dire financial situation”.Parent AF-KLM Group has pledged to provide a loan of up to €50m, partly to finance pilot lay-offs. Midex Airlines, beset by problems since it launched in 2008, has finally closed its doors for good.The carrier – at one point the largest all-cargo airline in the Gulf with a 10-strong fleet – had a chequered history. It began life as subsidiary of Midex International, a Lebanese courier with a hub at Paris-Orly. Seeing a chance to take on the integrators, founder Dr Issam Khairallah decided to launch airline services between France and the Middle East with a UAE operating certificate.It launched in Al-Ain, Abu Dhabi, in 2008 with A300Fs. But the airine struggled from the start.Most in the air freight business will remember that 2008 was a tough time – especially to launch a freighter airline. Midex faced serious competition from belly carriers and never quite found the volumes it was targeting from the Indian sub-continent, via Abu Dhabi, to Orly. By Alex Lennane 06/08/2015last_img read more

Self-exams aren’t helpful, and other surprising facts about breast cancer

first_img By Leah Samuel Jan. 13, 2016 Reprints New federal guidelines about mammograms have sparked another round of questions about how best to detect and treat breast cancer, which kills about 40,000 women in the United States each year. We’ve combed through the research to round up five surprising — and important — facts about the disease.Physical breast exams aren’t helpfulThey’re a staple of the annual checkup. And many gynecologists still urge women to do monthly self-exams. (So do some women’s magazines.) But the evidence shows there’s no benefit to manual breast exams, whether they’re performed by a physician or by the woman herself.So the American Cancer Society doesn’t recommend regularly getting, or doing, such exams. Instead, the group urges women to “be familiar with how their breasts normally look and feel and report any changes to a health care provider right away.”advertisement Tags breast cancerchemotherapymammograms HealthSelf-exams aren’t helpful, and other surprising facts about breast cancer Breast cancer kills about 40,000 women a year in the US. Chris Hondros/Getty Images If you have the earliest stage of breast cancer, your doctor may advise you to do nothing“Stage 0” cancer, formally called ductal carcinoma in situ, describes the early presence of cancerous or precancerous cells in milk ducts. It can indicate the possibility of a malignancy later in life, particularly for high-risk women, such as those with a strong family history of or genetic predisposition to breast cancer.DCIS can be treated with surgery or radiation. But some doctors are advising women at this stage to do nothing. A big study published last fall in JAMA Oncology looked at 100,000 women with DCIS. Most had lumpectomies or mastectomies — until recently, the standard treatment for “Stage 0” disease. Yet they still died of breast cancer at the same rate as women who were never diagnosed with DCIS.advertisement That evidence suggests “we should rethink our strategy,” Dr. Laura Esserman wrote in an editorial accompanying the study.The sit-and-wait approach is controversial, however. And doctors urge more vigilance, including the use of screening tests that are more sensitive than mammograms, in high-risk women.Magnetic resonance imaging “and ultrasound are important parts of the surveillance of these women,” said Dr. Len Lichtenfeld, deputy chief medical officer at the American Cancer Society. “They have to be watched very carefully.”For advanced cancer, surgery can sometimes be the first resortEven after cancer has spread, surgically removing the primary tumor appears to increase longevity in women with Stage IV breast cancer, according to a study of 21,000 women published last fall in the Journal of the American Medical Association.When cancer has spread, the conventional approach is chemotherapy, which reaches the whole body, or radiation. Going after the initial tumor with surgery “is a little counterintuitive,” said Mary Schroeder, assistant professor of health services research at the University of Iowa.But the study found that patients who underwent surgery in their first round of treatment had a median survival of 28 months, compared to 19 months for those who did not.Chemotherapy can discriminateFor certain aggressive types of breast cancer, the cure rates for African-American and Hispanic women are slightly lower than those for white or Asian women, according to an analysis published last fall in the Journal of Clinical Oncology.Researchers looked at outcomes for nearly 18,000 women with four types of aggressive, harder-to-treat forms of breast cancer. They all received chemotherapy prior to surgery.In the most dramatic example, a subgroup of nearly 6,000 women, the treatment eliminated tumors in 54 percent of the white women in the study, compared to 43 percent of the black women. No one seems to know why, said the study’s lead author, Dr. Brigid Killelea, a professor of surgery at Yale University.“That’s a difficult question,” she said. “The answer is probably multifactorial. And that’s why it’s so important to include black women and Hispanic women in clinical trials, and to encourage them to participate.”Breast cancer isn’t the most deadly cancer for women. But it is among the best funded.Lung cancer kills considerably more women in the United States than breast cancer each year.Nearly 72,000 women died last year from lung cancer and 40,000 died from breast cancer, according to the American Cancer Society.Breast cancer, however, still receives far more federal research funding than lung cancer. The National Institutes of Health spends about $685 million on breast cancer research, compared to $255 million on lung cancer.That works out to roughly $17,000 of research funding for every woman who dies from breast cancer in the United States, compared to less than $4,000 in research for every woman who dies from lung cancer.last_img read more

U.S. and Cuba Speak on Weapons Smuggling Claim

first_img Entire border patrol unit in North Hamgyong Province placed into quarantine following “paratyphoid” outbreak There are signs that North Korea is running into serious difficulties with its corn harvest By Daily NK – 2013.07.17 3:58pm AvatarDaily NKQuestions or comments about this article? Contact us at [email protected] News U.S. and Cuba Speak on Weapons Smuggling Claim News RELATED ARTICLESMORE FROM AUTHORcenter_img SHARE A North Korean ship seized by the Panamanian authorities on the 16th was searched because it might have been “smuggling narcotics,” rather than on suspicion of carrying arms, U.S. State Department press spokesman Patrick Ventrell revealed to reporters yesterday. However, it has since been revealed that the vessel may have been carrying “obsolete” weapons for repair in North Korea and subsequent return to Cuba.The Panamanian government initially claimed that the ship harbored missiles, with Panamanian President Ricardo Martinelli posting an image of the cargo hold on Twitter. This prompted Ventrell to note, “Any shipment of arms or related materiel would violate numerous UN Security Council resolutions – 1718, 1874, and 2094.” However, it has been confirmed that the vessel was carrying weapons, although their destination remains in dispute. The Cuban Ministry of Foreign Affairs denied in a statement that missiles destined for North Korea were on board. Instead, it explained that the weapons were Cold War-era defensive weapons on their way to be repaired by the North and eventually returned to Cuba (see below for the text of the Cuban statement).North Korea has not yet released any word on the subject. North Korea tries to accelerate building of walls and fences along border with China News Facebook Twitter News last_img read more

Goldman Sachs to manage National Bank Investments fund

first_img Montreal-based National Bank Investments Inc. (NBI) has added New York-based Goldman Sachs Asset Management LP (GSAM) to its roster of third-party portfolio managers, the National Bank of Canada subsidiary announced on Monday. “The partnership with Goldman Sachs Asset Management is made possible thanks to our 100% open architecture platform here at National Bank Investments,” says Jonathan Durocher, NBI’s president and CEO, in a statement. “This entrepreneurial culture enables us to attract the most reputable portfolio managers and to provide investors with a unique access to their expertise.” Change to Counsel Global Small Cap Fund Keywords Fund managersCompanies National Bank Investments Inc. Related news Share this article and your comments with peers on social media Franklin Templeton renames funds with new managerscenter_img NEO, Invesco launch four index PTFs The partnership means that the GSAM-managed National Bank Strategic U.S. Income and Growth Fund, which has a balanced U.S-focused approach that is tactical in nature and employs currency risk management in its fixed-income allocation, is now available to investors in Canada, notes James McNamara, global head, third-party distribution with GSAM. “We’re excited about expanding our investment management capabilities in Canada,” McNamara says in the statement. Tessie Sanci Facebook LinkedIn Twitterlast_img read more

NASAA compliance exams focus on seniors

first_imgTrump carrying out a “behind-the-scenes” war on regulation: NBF report New protections for senior investors on the horizon Related news The NASAA initiative, which included 62 compliance exams, focused largely on activity in senior client accounts and aimed to gather information from firms on their policies, procedures, and training related to seniors and other potentially vulnerable customers. Overall, the review found that only about 39% of firms had established written procedures addressing all of its concerns in this area, and 20% of the exams found that firms had not established written procedures addressing any of the areas. In particular, the regulators found potentially unsuitable recommendations to senior investors were identified in 10% of the exams. Of these instances, the product most commonly associated with potentially unsuitable recommendations is variable annuities. “There is a general concern with the sale of variable annuities to senior clients or those approaching retirement because of the penalty rates associated with early withdrawals,” NASAA says in a summary report of preliminary results. Potential suitability issues were also identified in connection with the sale of exchange-traded funds (ETFs), primarily non-traditional ETFs such as leveraged and inverse ETFs. About 30% of the suitability concerns involved equities. “In the exams that evinced suitability concerns, there was no correlation with lack of training as the suitability concerns almost all occurred in exams of firms that actually required training on both senior investor suitability and communicating with seniors,” the NASAA report says. “This finding should serve as a reminder to the industry that the mere existence of a training program, even a mandatory one, may not be enough if the training program is not adequately designed to effectively train representatives, if supervisors rely too heavily on the training, or if a firm ineffectively screens candidates at the hiring stage,” the report adds. The regulators also found that the majority of investor complaints continue to come from senior clients. “The rate of complaints filed by senior clients is disproportionately high,” the report says. This should remind firms that “improved communications with senior clients, and documentation of those communications, will not only serve these clients but will also serve an important risk-management purpose.” The NASAA review also found that only 24% of firms are requiring verification of senior clients’ profile information more frequently than every three years; and, that there appears to be limited development of “trusted contact forms” at firms, and very limited use of the forms even after they are developed. As well, about 62% of the exams found that firms have either established a formal committee, or designated at least one person, to focus on senior investor issues. “The preliminary findings from the coordinated examinations indicate that efforts to highlight the need for procedures that focus on senior investor matters have been successful at effecting change, but continued progress is necessary to best serve our aging population,” said NASAA president and Maine Securities Administrator, Judith Shaw, in a news release. “The preliminary findings indicate that many broker-dealers are taking valuable steps to develop procedures that are mindful of the common issues facing senior clients, however, they also identified areas where improvement is needed,” Shaw added. Photo copyright: surangaw/123RF James Langton Regulators aim to root out pandemic-driven liquidity issues Share this article and your comments with peers on social media U.S. broker-dealers still have a good deal of work to do to improve their dealings with senior clients, according to the preliminary results of compliance exams carried out by the North American Securities Administrators Association (NASAA) published on Monday. How dealers can protect vulnerable clients Keywords Compliance,  SeniorsCompanies North American Securities Administrators Association Facebook LinkedIn Twitterlast_img read more

Priti Patel publishes paper on group-based child sexual exploitation

first_imgPriti Patel publishes paper on group-based child sexual exploitation The Home Secretary has today published a paper on the characteristics of group-based child sexual exploitation offending making clear that more will be done by government, law enforcement and partners to better safeguard children and tackle perpetrators.The findings provide safeguarding partners with an overview of the current evidence in relation to group-based offending.The paper sets out the limited available evidence on the characteristics of offenders including how they operate, ethnicity, age, offender networks, as well as the context in which these crimes are often committed, along with implications for frontline responses and for policy development. An External Reference Group, consisting of independent experts on child sexual exploitation, reviewed and informed this work. Members included Labour MP for Rotherham Sarah Champion, Conservative MP for Wakefield Imran Ahmad Khan, survivor and campaigner Sammy Woodhouse, and Simon Bailey, National Police Chiefs Council lead on child protection.Home Secretary Priti Patel said:Victims and survivors of group-based child sexual exploitation have told me how they were let down by the state in the name of political correctness. What happened to these children remains one of the biggest stains on our country’s conscience.This paper demonstrates how difficult it has been to draw conclusions about the characteristics of offenders. That is why the government’s forthcoming Tackling Child Sexual Abuse Strategy will commit to improving our understanding of child sexual abuse – including around ethnicity.This will enable us to better understand any community and cultural factors relevant to tackling offending – helping us to safeguard children from abuse, deliver justice for victims and survivors, and restore the public’s confidence in the criminal justice system’s ability to confront this issue.Sammy Woodhouse said:It was extremely important for me to be a part of the External Reference Group as I was subjected to exploitation and abuse as a child and failed by authorities. Unfortunately this is something that is still happening today and will continue to happen in the future.As a country we still do not understand abuse and exploitation, and the government is not doing enough to prevent and tackle it, so I welcome the publication of this paper. I want perpetrators to be held to account for their criminal activity regardless of race or religion because unfortunately they haven’t, and it still remains a subject that we cannot openly discuss. No one should be exempt.The paper summarises studies which suggest individuals committing group-based child sexual exploitation are predominantly, but not exclusively, male and often under the age of 30. Some studies have indicated an over-representation of Asian and Black offenders. However, it is difficult to draw conclusions about the ethnicity of offenders as existing research is limited and data collection is poor.The lack of robust data on ethnicity and other factors is disappointing, however community and cultural factors are clearly relevant to understanding and tackling offending, and an approach to deterring, disrupting, and preventing offending tailored to the communities in which it occurs is needed.Therefore, a commitment to improve the collection and analysis of data on child sexual abuse, including in relation to characteristics of offenders such as ethnicity and other factors, will be included in the forthcoming Tackling Child Sexual Abuse Strategy to ensure the factors and context of offending are understood and confronted.Studies indicate that motivations differ between offenders, but that a sexual interest in children is not always the predominant motive. Financial gain and a desire for sexual gratification are common motives, and misogyny and disregard for women and girls may further enable the abuse.Offenders can come from a range of social backgrounds – some have been stable middle-class professionals, some of whom were married, whilst others have had more chaotic lifestyles. Materials used in the paper included published academic research, official statistics and published work by organisations working in the child sexual exploitation area, as well as a series of interviews with police officers and safeguarding officers involved in investigating this type of offending.Insight gained from this paper will be used to improve guidance to local agencies in identifying and disrupting this form of offending, and work with police to tackle organised exploitation by using improved analysis and sharing of data.The government will soon publish the Tackling Child Sexual Abuse Strategy, which will outline a whole system response to tackling all forms of child sexual abuse, including group-based offending.This paper will play an important role in the Strategy and its implementation, informing current and future work the government will undertake to tackle, prevent and disrupt this crime. The full paper /Public Release. This material comes from the originating organization and may be of a point-in-time nature, edited for clarity, style and length. View in full here. Why?Well, unlike many news organisations, we have no sponsors, no corporate or ideological interests. We don’t put up a paywall – we believe in free access to information of public interest. Media ownership in Australia is one of the most concentrated in the world (Learn more). Since the trend of consolidation is and has historically been upward, fewer and fewer individuals or organizations control increasing shares of the mass media in our country. According to independent assessment, about 98% of the media sector is held by three conglomerates. This tendency is not only totally unacceptable, but also to a degree frightening). Learn more hereWe endeavour to provide the community with real-time access to true unfiltered news firsthand from primary sources. It is a bumpy road with all sorties of difficulties. We can only achieve this goal together. Our website is open to any citizen journalists and organizations who want to contribute, publish high-quality insights or send media releases to improve public access to impartial information. You and we have the right to know, learn, read, hear what and how we deem appropriate.Your support is greatly appreciated. All donations are kept completely private and confidential.Thank you in advance!Tags:Asia, child sex, children, community, Criminal, criminal justice, Government, police chief, political correctness, research, Secretary, sexual abuse, sexual exploitation, statistics, Survivor, UK, UK Government, Wakefieldlast_img read more

Transforming UK into a life sciences superpower

first_imgTransforming UK into a life sciences superpower Thank you Richard, and I appreciate the opportunity to have this discussion. I’ve just got back from the Science Museum, where I’ve had my first jab.And the Queen was right – it doesn’t hurt a bit.I had Professor Van-Tam vaccinating me, which was a real honour. For me, having that in the Science Museum just underlined the significance of science and the life sciences. And having it from JVT, who has obviously played such an important role in this vaccine effort, it has been wonderful. And it really crystallised for me the job the life sciences have done over this past year, and, you know, how as an industry we moved with such extraordinary speed and helped to build the defences, in what effectively has been a race against time to save lives, that race is still on.We’ve seen some incredible results.One year ago, the number of people we could test for COVID in a day stood in 5 figures. Last month, we tested nearly 2 million people in a single day. That is because of advances in the diagnostics industry.Of course, back then we didn’t have treatments for COVID, so we found them – including for instance dexamethasone. And now of course we’re looking for more. And the estimate is the dexamethasone, the discovery of dexamethasone, has an impact on mortality, it has saved up to a million lives globally.Before the pandemic, of course, we didn’t make many vaccines in this country. Now we’re manufacturing millions.And we’ve achieved in months what usually takes years.Some of it we may never have achieved had it not been for the extraordinary circumstances that we’ve faced.And from what we started with, what we had at the start of this, a combination of elite research institutions, innovative regulation, pro-innovation regulation, and of course NHS and the NHS data, which has been such a powerful package. And one of the things I wanted to talk about today.It’s a real tribute to our life sciences sector, I think, and to members of the ABPI, and it’s a clear signal of what we can do, if we work together.I am incredibly proud to join the 34 million people who have had the jab now, and we’re getting more data that shows our vaccines are really reducing people’s chances of catching COVID, and we’re constantly finding out even more about the layers of protection that the vaccines are giving us.But despite this good news, we still face some real challenges right now. Around the world, there were more cases of COVID last week than any other week.But vaccines are not the only hope in this fight – we can also now see how important antivirals can be. And I just want to put antivirals on the agenda to this group, and this audience, because I think that they are very, very important for the future of how we handle this pandemic.First, they can treat people early, to stop mild disease becoming more serious.And secondly, as a prophylactic – as a precautionary measure – in settings where someone’s tested positive.So we’re absolutely determined to do more and learn from what we’ve achieved in the last year and a half on vaccines. With antivirals are the next frontier.We’ve just launched our antivirals taskforce – to do this year with antivirals what we did last year with vaccines.And the mission of that taskforce is to search for the most promising new drugs and speed up their development and manufacture here in the UK and have them ready for deployment this year.And we need to get to a world where we take our tests at home, and if you test positive, you take your antivirals at home.That is the next national mission – and I’m looking forward to working with a great many of you on it.We’ve learned a huge amount this last year – and we’ve learned a lot about how to make things happen. It’s one of the things I want to address today. How we’ve managed to accelerate things, that often happens in a crisis, but crucially, we’ve got to hold on to those things and translate the lessons we’ve learned, especially from the things that have gone well – the discovery of dexamethasone, our vaccines project.I name those 2 as the top 2 in this space, but there are many more. And we need to use these lessons, right across the board, not just in response to COVID, but more broadly too.And I just think it’s worth us all dwelling for a moment on the fact that the public has never been more engaged in health research – never has the public been more engaged about health research – so let’s harness this enthusiasm.Tackling COVID has been a global mission – but there are so many other noble missions that still lie ahead. I am sure you can think of those that you are most focused on.Tackling cancer. Treatments for dementia. Preventing heart disease. So much more.Now, over the last year, the NIHR and their ‘restart framework’ has helped support the recruitment of nearly a quarter of a million participants to non-urgent public health studies.And although it’s heartening that three quarters of commercial trials that had been paused have now re-opened, we’ve got to go further to recover non-COVID research.And the NIHR’s Clinical Research Network is providing targeted support for the recovery of studies that they – together with you – have identified as both vital and urgent. And I’m very grateful to ABPI and your membership for your instrumental role in this approach.And just looking ahead, that approach has got to be about more than just recovery.I think it’s very moving to hear the words of Stephen Hawking, he said that the true meaning of “intelligence is the ability to adapt to change”.So it’s no longer about getting us back to where we were – it’s about charting a new and better course, where we learn the lessons of the pandemic, and build back better, to transform the UK into a life sciences superpower. That is what we can do. I know it’s an ambition you all share.Under the banner of the 2017 life sciences strategy, which feels an age ago now, we’ve achieved a great deal together.We have got some great things to build on.The best life sciences though, just as you were saying, come from the collaboration of the holy trinity: of government, academia and industry.There are things that we must do, and by government I mean in the broadest sense, including the NHS, here are things that you must do. And we must do these things together.Today, I want to address 3 things of each – 3 things that we need to do, 3 things that you need to do, and then drill down into them.But really, in all cases, we need to do them together.First, on our side of the fence.How do we turn these ambitions into actions?The first thing I want to touch on is regulation and trial design. We have to take a hard look at our rules and regulations.They are of course the cornerstone of sector, practice, and getting new products into use with patients, but left unchecked, regulations can outgrow their original purpose and stifle innovation.Now, one of the quiet but very significant success stories of the pandemic has been the MHRA, and that’s because they have taken a culture and approach of focusing on safety, not bureaucracy, not simply taking step A then step B, then step C, because those are the steps that they’ve always taken, but running steps, A, B and C and D and E for that matter, concurrently at the same time.The result of this has been really clear for the whole world to see, because we were the first in the world to license a safe and effective clinically authorised vaccine, and we were quick out of the starting blocks with the recovery trial that identified dexamethasone and other treatments.And in my view, the MHRA has proved themselves to be one of the finest medical regulators in the world.But we can’t rest on our laurels, even during the pandemic, we legislated for the medicines and medical devices Bill, something we’re able to do now outside the EU, and that will allow us to build a regulatory system over time, that is one of the most effective in the world.That’s one of the most ready innovations in data and AI, advanced therapies, and technologies that don’t yet exist and none of us have yet dreamed of.And it’s at the heart of the bold vision we published last month for the future of UK clinical research delivery.The goal here is a country and a sector that’s ready to embrace the breakthrough technologies that can help us tackle some of the most pressing Population Health burdens in the future, and save and improve people’s lives.And for me, thinking about the purpose of this. The clue is in the name, life sciences are about saving and improving lives.An important part of that is to have trial designs that are not only, innovative, but interoperable across borders, too.And throughout the pandemic, we’ve been stung, when clinical trials aren’t designed with set standards from the start, meaning that it takes longer to translate the data, and longer to get the results that we have so desperately needed, changing that is something that I’ve put at the heart of our G7 presidency, because getting it right means that we’ll be able to get treatments out faster, and save more lives.And we’ve seen that for instance, on the link to the NHS through the accelerated access collaborative and through the some of the landmark commercial deals signed between the NHS and industry, like the deal signed with Novartis for Inclisiran, for instance which is incredibly impressive dynamic deal, and we’re becoming faster and better at getting new treatments and technologies into the hands of patients or clinicians in the NHS who need them.I just want to pause at this point, in particular to address a critical point that we all need to think about. Because when it comes to clinical trials, I also want us to think about women’s health.We recently launched the first ever Women’s Health Strategy – which aims to put an end to the ‘male by default’ culture, which I think has been around for far too long. And unbelievably still exists in some parts of what we do.Doing this involves changing how we spend our money, where our research goes and which conditions we put the most focus into.It means explicitly designing any clinical trial to be equal amongst men and women.I find it astonishing that it still doesn’t always happen today.We need to listen to women’s voices – and act on what we hear, so the life sciences are there for everyone.So that’s the first thing, research and clinical research and regulation, how it;s regulated, making sure that it is dynamic, modern, fit for purpose, where we have a big role to keep constantly making sure that we regulate for science and safety, and not for bureaucracy.The second thing I’m determined to get right is investment.So, despite the strong pipeline of SMEs spinning out of some of our world class science base here in the UK, it is still hard to access the late-stage capital these companies need to grow and turn into world-beaters.This is something our Life Sciences Investment Programme is intended to change, working again in partnership with you, with sovereign investors, and with the private sector, to deepen our investment ecosystem and support homegrown companies and homegrown talent.This is really incredibly important to me. It’s noticeable, for instance, going back to the vaccines programme, that many of the vaccines that are successful, were developed outside of the big pharma companies, and then partnered with the big, more established companies, in order to get to manufacturing scale and deployment capability. Really, really noticeable.And we’re already attracting some serious interest, including an 800 million investment from the Mubadala Investment Company, and I’m confident that there’ll be many more.I’m excited about what British life sciences companies can achieve, but we’ve got to lean in to unlock these new pools of growth capital and there’s a lot more to do on that front.The third thing is incredibly important to touch on, is skills.Clearly the greatest investment we can make is in people, we’ve got to drive up more children taking up STEM subjects, that drive is working.And we’ve seen an unprecedented growth in the number of students going for subjects like computer science, engineering, chemistry, physics, biology, we’ve seen a 400% increase in students wanting to study AI at university.We’re getting ahead of this, we have a life sciences 2030 skills strategy, and am absolutely determined that we stay ahead on this, we must maintain this focus on skill shortages where we see them.And again, keep working together to find solutions, whether that’s the uptake of apprenticeships in life sciences, or at the university of postgraduate level.This is the level of foresight and planning that we need, because you don’t become a superpower in life sciences by accident, and you can’t do it without the people who are the absolute bedrock of getting this right.So, these are the areas that were working in partnership, where we’re taking the lead on regulations on investment, on skills.But there are also the areas where industry can lead, and I just want to focus on 3 of these.And I think, I think these are incredibly important. Again we’ve got to work in partnership and together, but I just want to touch on three.First, manufacturing, and the location of manufacturing.We do some fantastic things here in the UK, we make surgical robots in Cambridge and hip replacements in Leeds and cancer medicines in Macclesfield.But there’s no question that when it comes to things like manufacturing medicines and vaccines on a commercial scale, we have fallen behind.Far too many British breakthroughs are then being manufactured elsewhere and imported back for UK patients.There was a dominant idea in government, that it didn’t matter where manufacturing took place, but I believe that is wrong, manufacturing, medicines and medical devices, bring jobs.And crucially, bring the whole process closer to patients and closer to research.So we’re changing that old way of thinking, COVID-19 has revealed how much our resilience to future emergencies really depends on our homegrown manufacturing capability.You know, we’ve now got “fill and finish” for the Oxford jab in Wrexham, we’ve got the vaccines being made on Teesside and in Livingston.There’s much more to come on this agenda, much, much more to come.We prove that we can build a manufacturing base in areas that we didn’t have, and we proved, we can do it quickly we’ve done this on vaccines, we’re doing it in diagnostics, we’ve committed 300 million to secure and scale up manufacturing capabilities here at home, including longer-term bets on some of the state of the art technology, we’re building our Cell and Gene Therapy Catapult Manufacturing Innovation Centre in Stevenage – which helps bring innovation, innovative cell and gene therapies to market.We’ve got our vaccines manufacturing and innovation centre in Oxfordshire on the way.And when these are complete, they’ll have the capacity to produce vaccines, on a scale for the entire UK population and to be able to export to other parts of the world, we’re just getting started on this, we are changing the attitude, we’re changing the approach, and we are leaning in.And the way to think about it is this.The UK is big enough, and has the capability enough, to be globally leading, but we’re also small enough to be joined up in a really good ecosystem.And we need to take a global approach here, there are some areas of the world where they consider the domestic market is big enough – that isn’t true.The NHS is a big buyer, one of the biggest, if not the biggest in the world. But we know that we need to take a global approach.And for me, I think that makes the perfect combination for investment in the life sciences.And my message to would-be investors in UK life sciences is this.Nowhere in the world, will you find a government that is more committed to you, and nowhere will you find a government more committed to free trade and contract law. The life sciences industry is global, by nature, it depends on a huge collaboration, internationally, on international supply chains, maybe more than any other industry.A typical vaccine contains 200 components from 80 companies, and 60 countries, and it’s the same for many therapeutics and devices.In Britain, we celebrate that huge collaboration that stands behind the success of all life sciences sector. We cherish the values of openness of scientific progress that that represents.So yes, of course, I recognise the huge pressure on trade and on supply chains in times of emergency, and I recognise some of the political pressures, of course I do.But we know, and I believe fundamentally that the best way to protect all our supply chains is not protectionism, it’s openness, we must keep that huge collaboration going, keep goods and services flowing.So I want to make crystal clear, Britain’s unshakeable commitment to free trade and contract law, a covenant on life sciences, if you like, that gives those who want to invest and build their businesses in the UK, the assurance they need that you can export the medicines, made here to your destination market.We want to match this commitment with powerful incentives, we’ve established the new Medicines and Diagnostics Manufacturing Transformation Fund as a model for how we can do this, offering capital grants to encourage manufacturing, including large-scale manufacturing, and my mission, our mission, not just to build back the manufacturing, but to build back better.Now I’m asking our Life Sciences Council to lead on this important work. And I want us to make sure our offer is so good, that it would be an impossible choice, not to invest and locate in the UK.So that’s the first thing.And I think this culture of working together, and openness, so that when you produce here, of course we’ll buy if it’s good, but you can export to anywhere in the world.This is a great moment to be taking this approach, because I think the life sciences are more visible and more valued than ever before by the public, and at the same moment, the technology is more powerful than ever before.So that brings me to the penultimate point I want to make. I want to focus on just one technology, which is incredibly important, where we need to drive things forward.And you need to take a lead. Fast and cheap sequencing is turning healthcare on its head.Let me tell you about a little girl called Jessica.She had trouble walking, she suffered epileptic fits, her parents did everything they could to find out what was wrong, going from consultant to consultant from scan to scan.Jessica was just 4 years old, and they couldn’t find out what was wrong.Now not only was this hugely costly to the NHS, but it was distressing for everyone involved.But when Jessica signed up to the 100,000 Genomes Project, all that changed. One sequence later, they found she had Glut One Deficiency Syndrome.It put an end to her diagnostic odyssey, it put her on the path to tailored treatment.In these cases of rare diseases, a typical diagnostic odyssey takes 4 to 7 years.But genomics is not just for tackling this huge problem in rare diseases.We’re making genomic sequencing a routine part of everyday diagnosis and treatment, and the UK again is uniquely placed.The NHS has the scale and the systems to make it happen.Turning tests around more quickly, prescribing precision medicine, giving doctors the tools to make better clinical decisions.So we’ll be backing genomics to the hilt.From our side, we need you.First, I’ve asked the Medical Research Council to develop a proposal for a UK Functional Genomics Initiative, through this initiative we want to make the UK a world leader in new approaches to understanding how genetic changes cause disease, and through that, the validation of drugs targets, later this year we’ll be launching our genome UK Implementation Plan.And I can confirm that we’re making further investments in some of Genomics England’s most cutting-edge projects, including the sequencing of newborns, in addressing the underrepresentation of ethnic minorities in genomic datasets, and funding next generation approaches to cancer diagnosis.Genomics is at the cutting edge, it’s helped save lives in this pandemic.And we in the UK are undisputed world leaders, and we’re going to keep on leading.Government, industry and academia. That Holy Trinity, working together.The very last point I want to make, is to absolutely underscore something that we all know, and has been proved yet again during this crisis, but still needs work to get the most out of – the importance of high quality integrated properly architectured data.Across the health and care system, people are using data more fluently and more effectively than ever before.Never more so than in clinical trials, again the recovery trial, allowed us to show what was possible.I want us to deliver on our vision to create the most advanced and data-enabled clinical research environment in the world, where initiatives like NHS DigiTrials have shown the way forward, but there’s much, much more to do.As well as the work internationally at the G7 level that I mentioned, today I’m proud to set out the next steps with a 20 million investment in the new data- driven Find, Recruit, and Follow-Up service for clinical trials.The gift we have here of the NHS in this country, means the opportunity to use data to save lives better than anywhere else, but that gift, if you allow me to stretch the analogy, that gift is not yet fully unwrapped.We have to work hard together to make best use of this gift to save lives.I’m determined to make it quicker and easier to set up and deliver the high power clinical trials we need, more than that, the trials will be better with R&D ready data, to strengthen their power to increase diversity of participants.And so, bring medicines to market safer and faster, from cancer to cardiovascular, to every disease known to mankind. Taken together, all this means better research, better treatment, better clinical decision making, and more lives saved, and lives improved, that is the mission of the life sciences.So, in closing, today I want to extend my gratitude to all of you, you’ve achieved some amazing things, which means that today we’re running ground-breaking clinical trials, we are treating COVID, we’re vaccinating our way out of this pandemic including me this morning.This has all been possible because of that Holy Trinity of government, academia and industry coming together to meet the challenges that we collectively share.But in my view, the best way for us to show that gratitude is to help you to do more, to take these steps, take them together and meet the challenges of the future.When we do that, we won’t just recover from this pandemic, but we’ll build back better. And together, working together, using the momentum that the pandemic has required, using the energy that it’s given the sector, using the enthusiasm that the British public have demonstrated for the scientific work that you’ve done, and the work to translate that science into reality.That is how we’re going to transform the UK, into a life sciences superpower, and I’m really excited about working with you to make it happen. /Public Release. This material comes from the originating organization and may be of a point-in-time nature, edited for clarity, style and length. View in full here. Why?Well, unlike many news organisations, we have no sponsors, no corporate or ideological interests. We don’t put up a paywall – we believe in free access to information of public interest. Media ownership in Australia is one of the most concentrated in the world (Learn more). Since the trend of consolidation is and has historically been upward, fewer and fewer individuals or organizations control increasing shares of the mass media in our country. According to independent assessment, about 98% of the media sector is held by three conglomerates. This tendency is not only totally unacceptable, but also to a degree frightening). Learn more hereWe endeavour to provide the community with real-time access to true unfiltered news firsthand from primary sources. It is a bumpy road with all sorties of difficulties. We can only achieve this goal together. Our website is open to any citizen journalists and organizations who want to contribute, publish high-quality insights or send media releases to improve public access to impartial information. You and we have the right to know, learn, read, hear what and how we deem appropriate.Your support is greatly appreciated. All donations are kept completely private and confidential.Thank you in advance!Tags:AI, Britain, British, Cambridge, EU, Europe, G7, Government, Hawking, health, Macclesfield, manufacturing, Oxford, Queen, stem, UK, UK Governmentlast_img read more